Volume 7 Supplement 1

Proceedings of the 13th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI)

Open Access

Digital cervicography and cold coagulation for cervical cancer screening in Nigeria

  • Clement Adebamowo1, 2Email author,
  • Maryam Almujtaba1,
  • Zahra Modibbo1,
  • Olayinka Olaniyan3 and
  • William Blattner1
Infectious Agents and Cancer20127(Suppl 1):P14

DOI: 10.1186/1750-9378-7-S1-P14

Published: 19 April 2012


Cervical cancer (CC) is most common cancer among women in Africa and in women living with HIV [1, 2]. Its prevalence has remained stable or increasing with introduction of HAART suggesting complex interactions with HIV [3, 4]. Current screening programs can substantially reduce all-cause mortality of CC but implementation in LMIC is hobbled by poor infrastructure, cost and lack of personnel. Nurse provider led, minimal visit, screen and treat programs offer an opportunity to reduce CC morbidity and mortality in LMIC [5]. In this study we evaluate the implementation of cervical cancer screen and treat programs at 2 HIV treatment and prevention sites in Nigeria.

Material and methods

CC screening programs using nurse providers, VIA, off the shelf camera for digital cervicography, treatment of eligible lesions by cold coagulation and referral as required was implemented at 2 PEPFAR supported sites in Abuja, Central Nigeria. QA was provided by Gynecologist and based on weekly review of digital cervicographs and client recall as required.


From July 2010 to July 2011, 2002 HIV+ women had been screened for CC at the 2 sites, but only data on 925 is reported in this abstract. Mean (SD) age was 35.2 (7.0) years; mean (sd) age at sexual debut was 19.0 (3.9) years; range, mean, sd of pregnancies was 0 – 16, 3.4, 2.5; range, mean, sd of pregnancies was 0 – 12, 1.6, 1.8; range, mean, sd of most recent cd4 count before screening was 11 – 1197, 466.7, 239.0; 6.8% were VIA positive; 0.2% had invasive CC and 0.2% were uncertain. Concordance between the clinical review and nursing diagnosis was 65% at the beginning of the program but reached 100% after 3 months.


This study showed nurse provider led CC screening and treatment program is a viable public health intervention among PLWHIV in Nigeria.



This study is supported by the IHV-UM Capacity Development for Research into AIDS Associated Malignancies (NIH/NCI D43CA153792-01 PI, Adebamowo) and IHV-UM AIDS International Training and Research Program (NIH/FIC D43TW001041-11 PI, Blattner).

Authors’ Affiliations

Office of Strategic Information, Research and Training, Institute of Human Virology
Department of Epidemiology, Institute of Human Virology, University of Maryland School of Medicine
National Hospital


  1. Boyle P, Levin B: World Cancer Report 2008. 2008, Geneva: International Agency for Research on CancerGoogle Scholar
  2. Clarke B, Chetty R: Postmodern cancer: the role of human immunodeficiency virus in uterine cervical cancer. Mol Pathol. 2002, 55: 19-24. 10.1136/mp.55.1.19.PubMed CentralView ArticlePubMedGoogle Scholar
  3. Mbulaiteye SM, Katabira ET, Wabinga H, Parkin DM, Virgo P, Ochai R, Workneh M, Coutinho A, Engels EA: Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-Cancer Registry Match Study. Int J Cancer. 2006, 118: 985-990. 10.1002/ijc.21443.View ArticlePubMedGoogle Scholar
  4. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S: Human papillomavirus and cervical cancer. Lancet. 2007, 370: 890-907. 10.1016/S0140-6736(07)61416-0.View ArticlePubMedGoogle Scholar
  5. Mwanahamuntu MH, Sahasrabuddhe VV, Kapambwe S, Pfaendler KS, Chibwesha C, Mkumba G, Mudenda V, Hicks ML, Vermund SH, Stringer JS, Parham GP: Advancing cervical cancer prevention initiatives in resource-constrained settings: insights from the Cervical Cancer Prevention Program in Zambia. PLoS Med. 2011, 8: e1001032-10.1371/journal.pmed.1001032.PubMed CentralView ArticlePubMedGoogle Scholar


© Adebamowo et al; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.